Swedish Orphan Biovitrum and Pharming sign Rhucin® distribution agreement

Stockholm, Sweden and Leiden, The Netherlands - April 15, 2010 - Swedish Orphan
Biovitrum (STO: BVT) and Pharming Group NV (NYSE Euronext: PHARM) today
announced an exclusive 10 year distribution agreement, under which Swedish
Orphan Biovitrum will distribute Rhucin(® )in 24 EU countries, Norway, Iceland
and Switzerland.

Under the agreement, Swedish Orphan Biovitrum will pay to Pharming an
undisclosed upfront payment and a regulatory approval milestone. In addition,
Swedish Orphan Biovitrum will pay a supply price that will include tiered
performance based royalties to Pharming. Swedish Orphan Biovitrum will also have
the right to participate in the future development and distribution of Rhucin(®
)in the agreed countries for( )additional indications.

Rhucin(®) is a recombinant human C1 inhibitor for the acute treatment of
Hereditary Angioedema (HAE) attacks. Pharming submitted an MAA for Rhucin(®) to
the European Medicines Agency (EMA) in September 2009.

"Rhucin(®) is a novel medicine that offers great value to HAE patients. This
orphan drug fits perfectly with our business goals and in our product portfolio.
We are very much looking forward to a longstanding partnership with Pharming and
the respective growth of both companies. We are delighted to provide what we
believe will be a highly beneficial medicine to patients who need it," said
Martin Nicklasson, CEO of Swedish Orphan Biovitrum Group.

"We are confident that we will successfully bring Rhucin(®) through the
remainder of the regulatory review process and look forward to making Rhucin(®)
available for HAE patients in Europe shortly thereafter. With their impressive
track record in selling and distributing medicines in the rare disease area in
Europe, Swedish Orphan Biovitrum makes an ideal partner to maximize the value of
our product in a mutually beneficial collaboration," said Dr. Sijmen de Vries,
Chief Executive Officer of Pharming.



About Rhucin(®) (conestat alfa)
Rhucin(®) or recombinant human C1 inhibitor (rhC1INH) is a recombinant protein
for acute treatment of  Hereditary Angioedema (HAE) attacks. Rhucin(® )has
identical amino acid sequence as endogenous human C1INH. The safety and efficacy
of Rhucin(® )has been demonstrated in two placebo controlled and four open-label
studies. Both randomized placebo-controlled clinical trials showed statistically
significant and clinically relevant improvement in time to relief of symptoms
and time to minimal symptoms compared to placebo. Rhucin(®) holds an orphan drug
designation both from the US FDA and EMA.



About Hereditary Angioedema
Hereditary Angioedema (HAE) is a debilitating and potentially life-threatening
genetic condition, resulting in spontaneous and recurring attacks of angioedema.
Angioedema attacks are characterized by swelling of soft tissue in a reaction
visually similar to severe allergic reactions. Attacks may affect various
locations such as the intestines, the face, extremities or mouth and throat.
Without treatment, attacks progress during the first 24 hours and then subside
over another two to five days. Attacks are painful and disfiguring and cause
significant morbidity. In addition to the life-threatening nature of the
disease, quality of life for individuals with the disease may be seriously
impaired.

HAE is caused by the lack or deficiency of endogenous C1INH activity, which
results in an overreaction of the immune system. Patients typically present in
late childhood, with the mean onset at 11 years. The prevalence of HAE is
approximately 1 in 30.000 individuals. The frequency of attacks varies
significantly in the affected population. Current treatment options include
prophylactic treatment with tranexamic acid and androgens, which may reduce the
frequency of attacks. The average frequency even under such anabolic steroid
prophylaxis is still estimated to be 6-8 treatment requiring attacks per year.
For the treatment of acute attacks, the current standard of care in Europe is
plasma derived C1 inhibitor from human donors. Swedish Orphan Biovitrum
estimates the current value of the European HAE market to approximately €110
million and sees the potential of the HAE market to increase with the
introduction of Rhucin(®) as one of several new treatment alternatives.



About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipe-line within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.



About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin(®) for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® is in early stage clinical development for Cockayne Syndrome and
lactoferrin for use in food products. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products,
as well as technology in the field of DNA repair (via DNage). Additional
information is available on the Pharming website, www.pharming.com
<http://www.pharming.com/>

This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.



For more information please contact:

Swedish Orphan Biovitrum:                Pharming Group NV:

Kennet Rooth, EVP Marketing & Sales      Marjolein van Helmond
Phone +46 8 412 98 43                    Phone: +31 6 109 299 54
Kennet.Rooth@swedishorphan.com           m.vanhelmond@pharming.com
<mailto:Kennet.Rooth@swedishorphan.com>  <mailto:m.vanhelmond@pharming.com>

Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com
<mailto:erik.kinnman@biovitrum.com>

Martin Nicklasson, CEO                   Sijmen de Vries, CEO
Phone: +46 8 697 20 00                   Phone: +31 71 52 47 400




Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 15, 2010 at 8:30 a.m. CET.



[HUG#1403857]